- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03664804
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
October 26, 2021 updated by: Hoffmann-La Roche
A Multi-Site, Prospective, Longitudinal, Cohort Study Measuring Cerebrospinal Fluid-Mutant Huntingtin Protein in Patients With Huntington's Disease
The study is designed as a multi-site, prospective, 15-month longitudinal, cohort study measuring CSF mHTT in participants with early manifest Stage I or Stage II Huntington's Disease (HD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
95
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 2B5
- The University of British Columbia; The Centre for Huntington Disease
-
-
Ontario
-
Markham, Ontario, Canada, L6B 1C9
- Centre for Movement Disorders (Neuropharm Consulting Inc.)
-
-
-
-
-
Berlin, Germany, 10117
- Charité - Universitätsmedizin Berlin, Campus Charité Mitte; Klinik für Psychiatrie und Psychotherapi
-
Bochum, Germany, 44791
- St. Josef and St. Elisabeth gGmbH ; St. Josef Hospital Bochum; Neurologisches Forschungszentrum
-
Ulm, Germany, 89081
- Universitätsklinikum Ulm; Klinik für Neurologie
-
-
-
-
-
Birmingham, United Kingdom, B15 2FG
- NIHR Welcome Trust Birmingham CRF - University Hospitals Birmingham; Department of Neuropsychiatry
-
Cardiff, United Kingdom, CF24 4HQ
- Cardiff University School of Medicine; Institute of Psychological Medicine Clinical Neurosciences
-
London, United Kingdom, WC1N 3BG
- National Hospital For Neurology and Neurosurgery
-
Manchester, United Kingdom, M13 9WL
- Central Manchester University Hospitals NHS Foundation Trust; Manchester Centre for Genomic Medicine
-
-
-
-
Colorado
-
Englewood, Colorado, United States, 80113
- Rocky Mountain Movement Disorders Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University; Research Division, Psychiatry
-
-
Kansas
-
Wichita, Kansas, United States, 67226
- Hereditary Neurological Disease Centre (HNDC)
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- John Hopkins University School of Medicine
-
-
New York
-
New York, New York, United States, 10032-3725
- Columbia University
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Health Science Center at Houston; McGovern Medical School
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Capacity to consent to participate in the study as assessed using the Evaluation to Sign Consent tool and investigator judgment
- Age 25 to 65 years, inclusive, at the time of signing Informed Consent Form
- Early manifest, Stage I or Stage II HD (defined as TFC of 7-13, inclusive)
- Genetically confirmed disease (CAG repeat length ≥ 36 in huntingtin gene by direct DNA testing)
- Body mass index ≥18 and ≤32 kg/m2; total body weight >50 kg
- Ability to undergo and tolerate MRI scans
- Ability to tolerate blood draws and lumbar puncture
- Ability and willingness to comply with all aspects of the protocol, including completion of interviews and questionnaires and carrying/wearing of a digital monitoring device
- Stable medical, psychiatric, and neurological status for at least 12 weeks prior to screening and at the time of enrollment
- Signed study companion consent for participation, if a study companion is available
- For women of childbearing potential: agreement to remain abstinent or use acceptable contraceptive methods during the observational period
Exclusion Criteria:
- Any condition, including severe chorea, that would prevent either writing or performing pen and paper or smartphone-based tasks
- History of attempted suicide or suicidal ideation with plan (i.e., active suicidal ideation) that required hospital visit and/or change in level of care within 12 months prior to screening
- Current active psychosis, confusional state, or violent behavior
- Any serious medical condition or clinically significant laboratory, vital sign, or electrocardiogram abnormalities at screening that, in the investigator's judgement, precludes the participant's safe participation in and completion of the study
- Pregnant or breastfeeding, or intending to become pregnant during the study
- Positive for hepatitis C virus antibody or hepatitis B surface antigen at screening
- Known HIV infection
- Current or previous use of an antisense oligonucleotide (including small interfering RNA)
- Current use of antipsychotics prescribed for psychosis, cholinesterase inhibitors, memantine, amantadine, or riluzole including use within 12 weeks of enrollment
- Treatment with an investigational drug within 30 days prior to screening or 5 half-lives of the investigational drug, whichever is longer
- Antiplatelet or anticoagulant therapy within the 14 days prior to screening or anticipated use during the study, including, but not limited, to aspirin (unless ≤81mg/day), clopidogrel, dipyridamole, warfarin, dabigatran, rivaroxaban, and apixaban
- History of bleeding diathesis or coagulopathy; platelet count < lower limit of normal unless stable and assessed by the Investigator and Sponsor Medical Monitor to be not clinically significant
- Malignancy within 5 years prior to screening, except basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated
- History of gene therapy or cell transplantation or any other experimental brain surgery
- Concurrent or planned concurrent participation in any clinical study without approval of the Medical Monitor
- Presence of implanted shunt for the drainage of CSF or an implanted CNS catheter
- Pre-existing structural brain lesion as assessed by MRI scan
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Participants with Early Manifest Stage I or II HD
No study drug was administered in this study
|
No study drug was administered in this study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in the Following Clinical Endpoints at 3, 9, and 15 Months: cUHDRS, TFC, TMS, SDMT, SWR Test, and IS
Time Frame: Baseline to 15 months
|
cUHDRS = composite Unified Huntington's Disease Rating Scale TFC = Total Functional Capacity Scale TMS = Total Motor Scale SDMT = Symbol Digit Modalities Test SWR = Stroop Word Reading IS = Independence Scale
|
Baseline to 15 months
|
Change from Baseline in Biomarkers of Neuronal Injury (e.g., CSF NfL and tau) at 3, 9, and 15 Months
Time Frame: Baseline to 15 Months
|
CSF = Cerebrospinal Fluid NfL = Neurofilament Light Chain
|
Baseline to 15 Months
|
Change from Baseline in Brain Atrophy Endpoints (e.g., Whole Brain Volume Decline, Caudate Volume Decline) as Determined by Brain MRI, at 3, 9, and 15 Months
Time Frame: Baseline to 15 Months
|
Baseline to 15 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Within-Participant Change from Baseline in CSF mHTT Levels at 3, 9, and 15 Months
Time Frame: Baseline to 15 Months
|
mHTT=Mutant Huntingtin Protein
|
Baseline to 15 Months
|
Association of Change from Baseline in Clinical Measures (cUHDRS, TFC, TMS, SDMT, SWR, and IS) at 3, 9, and 15 Months
Time Frame: Baseline to 15 Months
|
Baseline to 15 Months
|
|
Association of Change from Baseline in Biomarkers of Neuronal Injury (e.g., CSF NfL and tau) at 3, 9, and 15 Months
Time Frame: Baseline to 15 Months
|
Baseline to 15 Months
|
|
Association of Change from Baseline in Brain Atrophy Endpoints, as Determined by Brain MRI at 3, 9, and 15 Months
Time Frame: Baseline to 15 Months
|
Baseline to 15 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 5, 2018
Primary Completion (Actual)
May 7, 2021
Study Completion (Actual)
May 7, 2021
Study Registration Dates
First Submitted
September 7, 2018
First Submitted That Met QC Criteria
September 7, 2018
First Posted (Actual)
September 11, 2018
Study Record Updates
Last Update Posted (Actual)
October 27, 2021
Last Update Submitted That Met QC Criteria
October 26, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Dyskinesias
- Heredodegenerative Disorders, Nervous System
- Dementia
- Cognition Disorders
- Chorea
- Huntington Disease
Other Study ID Numbers
- BN40422
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Huntington's Disease
-
Massachusetts General HospitalCompletedHuntington's Disease (HD)United States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
SOM Innovation Biotech SACompleted
-
Sanguine BiosciencesHoffmann-La RocheRecruitingHuntington Disease | Huntington's Dementia | Huntington Disease, Late Onset | Huntington; Dementia (Etiology)United States
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
PfizerMedivation, Inc.CompletedAlzheimer's Disease | Huntington's DiseaseUnited States
-
PfizerMedivation, Inc.CompletedHuntington Disease | Alzheimer's DiseaseUnited States
-
Hoffmann-La RocheCompleted
-
PfizerMedivation, Inc.CompletedAlzheimer's Disease | Huntington's DiseaseUnited States
-
PfizerMedivation, Inc.CompletedAlzheimer's Disease | Huntington's DiseaseUnited States
Clinical Trials on No Study Drug was Administered in this Study
-
VA Puget Sound Health Care SystemCompletedChronic Obstructive Pulmonary Disease
-
Yale-NUS CollegeCompletedADHD | Conduct Disorder | Oppositional Defiant Disorder
-
Kerman University of Medical SciencesCompletedPrediction Hypothyroidism Patients Using Machine Learning Algorithms | Identification of Important Symptoms of HypothyroidismIran, Islamic Republic of
-
Changhua Christian HospitalCompleted
-
Tianjin Happy Life Technology Co., Ltd.Unknown
-
Aga Khan University Hospital, PakistanCompleted
-
Xuanwu Hospital, BeijingActive, not recruiting
-
Boston IVFCompleted